Evaluating the effects of Empagliflozin on body composition in type 2 diabetes
Decrease in Body Fat and Increase in Ketone Body After 6-month Treatment of Empagliflozin in Korean Patients With Type 2 Diabetes
This study is testing if the diabetes medication Empagliflozin can help people with type 2 diabetes lose weight and improve their body composition and metabolism.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | Seoul National University Bundang Hospital Academic / other |
| Locations | 1 site (Seongnam, Gyeonggi) |
| Trial ID | NCT03877406 on ClinicalTrials.gov |
What this trial studies
This study aims to assess how the SGLT2 inhibitor Empagliflozin affects body composition and metabolic outcomes in individuals with type 2 diabetes in Korea. By promoting glucose excretion through urine, the medication may lead to weight loss, but the specific impact on fat composition and metabolic health is being investigated. Participants will receive Empagliflozin and undergo evaluations to determine changes in body fat and metabolic markers.
Who should consider this trial
Good fit: Ideal candidates are adults aged 20-79 with type 2 diabetes, a BMI of 20 kg/m2 or higher, and an eGFR of 45 or greater.
Not a fit: Patients with type 1 diabetes, secondary diabetes, or those using insulin may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into effective weight management and metabolic improvements for patients with type 2 diabetes.
How similar studies have performed: Other studies have shown positive outcomes with SGLT2 inhibitors in managing diabetes, suggesting this approach has potential based on previous findings.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients with type 2 diabetes Age: 20-79 years BMI ≥ 20 kg/m2 eGFR ≥ 45 Exclusion Criteria: Patients with type 1 diabetes Secondary diabetes due to Cushing diseases, acromegaly Insulin user BMI \< 20 kg/m2 eGFR \< 45 Malignancy
Where this trial is running
Seongnam, Gyeonggi
- Seoul National University Bundang Hospital — Seongnam, Gyeonggi, Korea, Republic of (Recruiting)
Study contacts
- Principal investigator: Soo N Lim, MD, PHD — Seoul National University Bundang Hospital
- Study coordinator: Yujin N Shin, MD
- Email: 54256@snubh.org
- Phone: 82-31-787-7035
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.